BR112022017425A2 - Usos terapêuticos de compostos macrocíclicos - Google Patents

Usos terapêuticos de compostos macrocíclicos

Info

Publication number
BR112022017425A2
BR112022017425A2 BR112022017425A BR112022017425A BR112022017425A2 BR 112022017425 A2 BR112022017425 A2 BR 112022017425A2 BR 112022017425 A BR112022017425 A BR 112022017425A BR 112022017425 A BR112022017425 A BR 112022017425A BR 112022017425 A2 BR112022017425 A2 BR 112022017425A2
Authority
BR
Brazil
Prior art keywords
therapeutic uses
macrocyclic compounds
compounds
mammals
compositions
Prior art date
Application number
BR112022017425A
Other languages
English (en)
Portuguese (pt)
Inventor
William Murray Brion
Zhai Dayong
J Cui Jingrong
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of BR112022017425A2 publication Critical patent/BR112022017425A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112022017425A 2020-03-02 2021-03-01 Usos terapêuticos de compostos macrocíclicos BR112022017425A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062984159P 2020-03-02 2020-03-02
PCT/US2021/020255 WO2021178296A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Publications (1)

Publication Number Publication Date
BR112022017425A2 true BR112022017425A2 (pt) 2022-11-29

Family

ID=77613771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017425A BR112022017425A2 (pt) 2020-03-02 2021-03-01 Usos terapêuticos de compostos macrocíclicos

Country Status (11)

Country Link
US (1) US20250262216A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114530A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023515687A (cg-RX-API-DMAC7.html)
KR (1) KR20230022151A (cg-RX-API-DMAC7.html)
CN (1) CN115397514A (cg-RX-API-DMAC7.html)
AU (1) AU2021229457A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017425A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174455A1 (cg-RX-API-DMAC7.html)
IL (1) IL295938A (cg-RX-API-DMAC7.html)
MX (1) MX2022010945A (cg-RX-API-DMAC7.html)
WO (1) WO2021178296A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
AU2017302019A1 (en) * 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
WO2021063276A1 (zh) * 2019-09-30 2021-04-08 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
IL295938A (en) 2022-10-01
EP4114530A1 (en) 2023-01-11
WO2021178296A1 (en) 2021-09-10
JP2023515687A (ja) 2023-04-13
AU2021229457A1 (en) 2022-10-20
CA3174455A1 (en) 2021-09-10
US20250262216A1 (en) 2025-08-21
KR20230022151A (ko) 2023-02-14
EP4114530A4 (en) 2024-04-17
MX2022010945A (es) 2022-10-07
CN115397514A (zh) 2022-11-25

Similar Documents

Publication Publication Date Title
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
MX383823B (es) Macrociclos de diarilo quirales y usos de los mismo.
MX386680B (es) Polimorfo de macrociclo de diarilo.
CO2021005226A2 (es) Nuevos compuestos antihelmínticos
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
ECSP056138A (es) Dihidroquinazolinas sustituidas
BR112015013700A8 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
BR112014031394A8 (pt) Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
BR112022023025A2 (pt) Moduladores de htt para tratar doença de huntington
UY28130A1 (es) Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso.
EA200701113A1 (ru) Макролиды
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
DOP2024000254A (es) Macrociclos de indazol y su uso
UY39061A (es) Inhibidores macrocíclicos de rip2-cinasa
CO2026005573A2 (es) Compuestos heterobifuncionales y métodos de tratamiento de enfermedades
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
CL2022002239A1 (es) Tafoxiparina para el tratamiento de la preeclampsia
MX2022010945A (es) Usos terapeuticos de compuestos macrociclicos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2869 DE 30-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.